Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lorus Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Troy Griffin who wrote (274)	3/15/2000 6:41:00 PM
From: Creative	Read Replies (1) \| Respond to of 279

Thanks for the post. Sell off continued today dropping to $4.05 and the rebounding to $5.55 after the following news release. Lorus Therapeutics Inc - Lorus Therapeutics drugs unaffected by access call Lorus Therapeutics Inc LOR Shares issued 78,751,668 2000-03-14 close $5.5 Wednesday Mar 15 2000 An anonymous director reports Lorus Therapeutics's lead anticancer drugs will not be affected by president Bill Clinton and British prime minister Tony Blair's call for universal access to the data related to the Human Genome Project (the mapping of human genes). The success of Lorus's technologies is not related to the genome project. Specifically, Lorus's three key platform technologies represented by Virulizin, GTI-2040 and GTI-2501 and NC 381 will not be impacted by yesterday's news. Lorus recently reported that the U.S. Food and Drug Administration had approved the company's investigational new drug application to begin clinical trials of the anticancer drug, GTI-2040. The clinical trials are underway under the direction of Dr. Richard Schilsky of the University of Chicago Cancer Research Centre. WARNING: The company relies on litigation protection for "forward-looking" statements. (c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com old url (better for printing)